The FDA’s new GRAS notification rule closes the self-affirmation pathway that has let companies add new ingredients to the food supply without ever telling the agency.
What The Proposed Rule Actually Changes
For nearly three decades, food manufacturers have had two routes to market a new ingredient. They could submit a formal GRAS notice to the FDA and wait for a “no questions” letter, or they could convene their own panel of experts, self-affirm the ingredient as safe, and skip the agency entirely. That second route has never required public disclosure, which means there is no complete inventory of what has actually entered the U.S. food supply this way.
The rule proposed this week would shift that second pathway from voluntary to mandatory. Companies introducing a new ingredient would need to notify the FDA and explain why they believe it’s safe. Manufacturers already using self-affirmed ingredients would also need to submit data through what the agency is calling a streamlined pathway, rather than restarting the process from scratch. Substances that already went through full GRAS review and received a “no safety questions” letter are exempt.
Acting FDA Commissioner Kyle Diamantas framed the change as closing a “decades-old information gap” that leaves the agency unable to fully account for what’s on the market. The self-affirmation option was introduced in 1997, when the FDA said it could no longer devote the resources needed to review every ingredient notice on its own.
Timelines And What Comes Next
Under the proposal, the FDA would have 45 days to confirm a submission is complete, followed by a 180-day window to issue a safety determination. That’s a tighter clock than the current voluntary system, where full reviews have commonly stretched past five months even though the formal target has also been 180 days.
The rule is now open for public comment, with reporting pointing to a roughly 120-day comment window before any final version is published. Companies can continue bringing new ingredients to market while that process plays out, since the FDA has been clear the proposal doesn’t pause commercial activity during evaluation.
Separately, HHS and USDA have submitted a proposed definition of ultra-processed foods for review, though officials haven’t detailed timing on that piece.
The Legal Question Hanging Over It
The FDA has previously acknowledged, in the preamble to its 2016 GRAS final rule, that it lacks explicit statutory authority to force companies to file GRAS notices. That admission is now central to the pushback from industry attorneys, particularly with a recent Supreme Court ruling that narrowed how much deference courts give federal agencies interpreting ambiguous statutes.
Diamantas addressed this directly on the press call, saying the agency is working with Congress on legislative options to put the GRAS framework and broader nutrition reform on firmer statutory footing. Until that happens, any final rule is likely to face challenges over whether the FDA can compel disclosure through rulemaking alone, or whether it needs Congress to act first.
Buyer And Procurement Implications
For procurement and ingredient sourcing teams, the practical impact will build slowly rather than hit all at once. A public GRAS inventory, if implemented as described, would give buyers a new due-diligence tool: the ability to check whether a supplier’s self-affirmed ingredient has actually been disclosed to the FDA, rather than relying solely on the supplier’s own paperwork.
Sourcing teams working with ingredient suppliers who currently rely on self-affirmation should expect requests for additional safety documentation as the rule moves through comment and finalization, particularly for ingredients without an existing “no questions” letter. Contracts and supplier qualification processes that reference GRAS status may need updating once the final scope of the streamlined submission pathway is clear, since the current proposal text and the FDA’s public comments haven’t fully aligned on whether “certain uses” or “all new substances” will be covered.
Given the multi-year runway to a final rule, this is a watch-and-prepare item rather than an immediate compliance deadline.
FAQ
Does the new GRAS rule take effect immediately?
No. The rule is currently open for public comment, and legal analysts expect a final rule to take another two to three years given the standard rulemaking process and likely litigation.
Which ingredients are exempt from the new notification requirement?
Substances already listed or affirmed as GRAS by regulation, or those for which the FDA has already issued a formal “no safety questions” letter, would not need to be resubmitted under the proposal.
Can companies still launch new ingredients while the rule is pending?
Yes. The FDA has confirmed companies can continue bringing ingredients to market during the evaluation period; the proposal does not pause current market activity.
Sources
- Food Dive, “FDA lays out plan to close ingredients ‘loophole’ targeted by RFK Jr,” Aug. 10, 2026
- FoodNavigator, “FDA GRAS overhaul: HHS proposes mandatory notification,” Aug. 10, 2026
- Food Processing, “New Details Emerge on FDA’s GRAS Rulemaking”
- AgFunderNews, “There are ‘credible legal questions as to whether FDA has the legal authority to eliminate self-GRAS'”
- Verdant Law, “GRAS Reform Update: Where Do Things Stand?”
- HHS.gov, “HHS Secretary Kennedy Directs FDA to Explore Rulemaking to Eliminate Pathway for Companies to Self-Affirm Food Ingredients Are Safe”